Affiliation:
1. Division of Cardiology Department of Medicine The Johns Hopkins Hospital Baltimore MD
2. Division of Cardiology Department of Medicine Medical University of South Carolina Charleston SC
3. Division of Cardiology Department of Medicine Duke University School of Medicine Durham NC
Abstract
Background
Arrhythmogenic right ventricular cardiomyopathy/dysplasia (
ARVC
/D) is characterized by high arrhythmic burden and progressive heart failure, which can prompt referral for heart transplantation. Cardiopulmonary exercise testing (
CPET
) has an established role in risk stratification for advanced heart failure therapies, but has not been described in
ARVC
/D. This study sought to determine the safety and prognostic utility of
CPET
in patients with
ARVC
/D.
Methods and Results
Using the Johns Hopkins
ARVC
/D Registry, we examined patients with
ARVC
/D undergoing
CPET
. Baseline characteristics and transplant‐free survival were compared on the basis of peak oxygen consumption (pVO2) (≤14 or >14 mL/kg per minute) and ventilatory efficiency (Ve/
VCO
2
slope ≤34 or >34). Thirty‐eight patients underwent 50
CPET
s. There were no sustained arrhythmic events. Twenty‐nine patients achieved a maximal test. Patients with pVO2 ≤14 mL/kg per minute were more often men (
P
=0.042) compared with patients with pVO2 >14 mL/kg per minute. Patients with Ve/
VCO
2
slope >34 tended to have more moderate/severe right ventricular dilation (7/9 [78%] versus 10/26 [38%];
P
=0.060) and clinical heart failure (8/9 [89%] versus 13/26 [50%];
P
=0.056) compared with patients with Ve/
VCO
2
slope ≤34. Patients who underwent heart transplantation were more likely to have clinical heart failure (10/10 [100%] versus 13/28 [46%];
P
=0.003). Patients with Ve/
VCO
2
slope >34 had worse transplant‐free survival compared with patients with Ve/
VCO
2
slope ≤34 (n=35; hazard ratio, 6.57 [95%
CI
, 1.28–33.72]; log‐rank
P
=0.010), whereas transplant‐free survival was similar on the basis of pVO2 groups (n=29; hazard ratio, 3.38 [95%
CI
, 0.75–15.19]; log‐rank
P
=0.092).
Conclusions
CPET
is safe to perform in patients with
ARVC
/D. Ve/
VCO
2
slope may be used for risk stratification and guide referral for heart transplantation in
ARVC
/D.
Publisher
Ovid Technologies (Wolters Kluwer Health)
Subject
Cardiology and Cardiovascular Medicine
Cited by
20 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献